Control-IQ Technology Positively Impacts Patient Reported Outcome Measures and Glycemic Control in Youth with Type 1...

Area of Science:

• Endocrinology and Metabolism
• Pediatric Diabetes Technology

Background:

• Type 1 diabetes (T1D) management in youth requires advanced tools for optimal glycemic control and quality of life.
• The Tandem t:slim X2 insulin pump with Control-IQ technology represents a significant advancement in automated insulin delivery systems.

Purpose of the Study:

• To evaluate the real-world impact of the t:slim X2 insulin pump with Control-IQ technology on quality of life and glycemic control in pediatric patients with T1D.
• To assess the effects of this technology on both the youth with T1D and their parents.

Main Methods:

• A single-center, prospective study involving 59 pediatric patients (6-18 years) with T1D initiating Control-IQ technology.
• Validated patient-reported outcome measures (PROMs) and glycemic control metrics were collected at baseline and over 16 weeks.
• Measures included diabetes impact, device satisfaction, hypoglycemia fear, and well-being, alongside time in range.

Main Results:

• Significant improvements were observed in youth and parents' scores for diabetes impact, device satisfaction, and hypoglycemia fear.
• Mean time in glycemic range increased substantially from 52.6% at baseline to 62.6% at 4 weeks, sustained to 16 weeks.
• While youth expectations remained favorable, parental perception of the technology's impact was lower (p=0.04).

Conclusions:

• Initiating Control-IQ technology in a real-world setting demonstrably enhances quality of life and glycemic control for youth with T1D.
• The technology offers tangible benefits for both patients and their caregivers, simplifying diabetes management.
• This study confirms the efficacy of advanced automated insulin delivery systems in improving daily life and health outcomes.